Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
804,525
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
132,993
-
Shares change
-
+132,993
-
Total reported value, excl. options
-
$876,125
-
Value change
-
+$876,125
-
Number of buys
-
8
-
Price
-
$6.58
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q3 2022
8 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q3 2022.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 132,993 shares
of 804,525 outstanding shares and own 16.53% of the company stock.
Largest 9 shareholders include ARMISTICE CAPITAL, LLC (90,000 shares), SABBY MANAGEMENT, LLC (15,284 shares), MILLENNIUM MANAGEMENT LLC (13,922 shares), BANK OF AMERICA CORP /DE/ (6,770 shares), UBS Group AG (5,797 shares), Tower Research Capital LLC (TRC) (1,067 shares), MORGAN STANLEY (134 shares), Federation des caisses Desjardins du Quebec (19 shares), and TD Waterhouse Canada Inc. (85 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.